Article: A meta-analysis on intravenous magnesium sulphate for treating acute asthma

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleA meta-analysis on intravenous magnesium sulphate for treating acute asthma
AuthorsCheuk, DKL1
Chau, TCH2
Lee, SL
Issue Date2005
PublisherB M J Publishing Group. The Journal's web site is located at http://www.archdischild.com/
CitationArchives of Disease in Childhood, 2005, v. 90 n. 1, p. 74-77 [How to Cite?]
DOI: http://dx.doi.org/10.1136/adc.2004.050005
AbstractAIM: To evaluate the effectiveness of intravenous magnesium sulphate in the treatment of acute asthmatic attacks in children by meta-analysis. METHODS: A systematic and comprehensive search of the literature was performed to identify controlled clinical trials of magnesium sulphate in paediatric acute asthma which evaluated outcomes of hospitalisation or short term pulmonary function tests or symptom scores. Unpublished data were searched by personal contacts with authors and specialists. Two reviewers independently assessed trial qualities and synthesised data. Heterogeneity among studies was evaluated by the Cochrane Q test. Outcome data were pooled by random or fixed effect models depending on presence or absence of heterogeneity. RESULTS: Five randomised placebo controlled trials involving a total of 182 patients were identified. They compared intravenous magnesium sulphate to placebo in treating paediatric patients with moderate to severe asthmatic attacks in the emergency department, with co-therapies of inhaled beta2 agonists and systemic steroids. The studies were of high quality with results judged to be valid. Four studies showed that magnesium sulphate was effective, while one study found it ineffective. There was no significant heterogeneity in the primary outcome of hospitalisation. In the fixed effect model, magnesium sulphate is effective in preventing hospitalisation (OR 0.290, 95% CI 0.143 to 0.589). The number needed to treat is 4 (95% CI 3 to 8). Secondary outcomes of short term pulmonary function tests and clinical symptom scores also showed significant improvement. CONCLUSION: Intravenous magnesium sulphate probably provides additional benefit in moderate to severe acute asthma in children treated with bronchodilators and steroids.
ISSN0003-9888
2011 Impact Factor: 2.881
2011 SCImago Journal Rankings: 0.199
DOIhttp://dx.doi.org/10.1136/adc.2004.050005
ISI Accession Number IDWOS:000225865900019
PubMed Central IDPMC1720072
DC Field
Value
dc.contributor.authorCheuk, DKL
dc.contributor.authorChau, TCH
dc.contributor.authorLee, SL
dc.date.accessioned2007-10-30T06:19:56Z
dc.date.available2007-10-30T06:19:56Z
dc.date.issued2005
dc.description.abstractAIM: To evaluate the effectiveness of intravenous magnesium sulphate in the treatment of acute asthmatic attacks in children by meta-analysis. METHODS: A systematic and comprehensive search of the literature was performed to identify controlled clinical trials of magnesium sulphate in paediatric acute asthma which evaluated outcomes of hospitalisation or short term pulmonary function tests or symptom scores. Unpublished data were searched by personal contacts with authors and specialists. Two reviewers independently assessed trial qualities and synthesised data. Heterogeneity among studies was evaluated by the Cochrane Q test. Outcome data were pooled by random or fixed effect models depending on presence or absence of heterogeneity. RESULTS: Five randomised placebo controlled trials involving a total of 182 patients were identified. They compared intravenous magnesium sulphate to placebo in treating paediatric patients with moderate to severe asthmatic attacks in the emergency department, with co-therapies of inhaled beta2 agonists and systemic steroids. The studies were of high quality with results judged to be valid. Four studies showed that magnesium sulphate was effective, while one study found it ineffective. There was no significant heterogeneity in the primary outcome of hospitalisation. In the fixed effect model, magnesium sulphate is effective in preventing hospitalisation (OR 0.290, 95% CI 0.143 to 0.589). The number needed to treat is 4 (95% CI 3 to 8). Secondary outcomes of short term pulmonary function tests and clinical symptom scores also showed significant improvement. CONCLUSION: Intravenous magnesium sulphate probably provides additional benefit in moderate to severe acute asthma in children treated with bronchodilators and steroids.
dc.description.naturepublished_or_final_version
dc.format.extent166274 bytes
dc.format.extent1778 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.identifier.citationArchives of Disease in Childhood, 2005, v. 90 n. 1, p. 74-77 [How to Cite?]
DOI: http://dx.doi.org/10.1136/adc.2004.050005
dc.identifier.citeulike3401720
dc.identifier.doihttp://dx.doi.org/10.1136/adc.2004.050005
dc.identifier.isiWOS:000225865900019
dc.identifier.issn0003-9888
2011 Impact Factor: 2.881
2011 SCImago Journal Rankings: 0.199
dc.identifier.openurl
dc.identifier.pmcidPMC1720072
dc.identifier.pmid15613519
dc.identifier.scopuseid_2-s2.0-11144229833
dc.identifier.urihttp://hdl.handle.net/10722/45209
dc.languageeng
dc.publisherB M J Publishing Group. The Journal's web site is located at http://www.archdischild.com/
dc.rightsArchives of Disease in Childhood. Copyright © B M J Publishing Group.
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License
dc.subject.meshAnti-Asthmatic-Agents-administration-and-dosage
dc.subject.meshAsthma-drug-therapy
dc.subject.meshMagnesium-Sulfate-administration-and-dosage
dc.titleA meta-analysis on intravenous magnesium sulphate for treating acute asthma
dc.typeArticle
Author Affiliations
  1. The University of Hong Kong
  2. Hong Kong Baptist University